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Genomic expression catalogue of 
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adaptations
Abdallah M. Abdallah1,*, Grant A. Hill-Cawthorne1,2,*, Thomas D. Otto3, Francesc Coll4, 
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Although Bacillus Calmette-Guérin (BCG) vaccines against tuberculosis have been available for more 
than 90 years, their effectiveness has been hindered by variable protective efficacy and a lack of 
lasting memory responses. One factor contributing to this variability may be the diversity of the BCG 
strains that are used around the world, in part from genomic changes accumulated during vaccine 
production and their resulting differences in gene expression. We have compared the genomes and 
transcriptomes of a global collection of fourteen of the most widely used BCG strains at single base-
pair resolution. We have also used quantitative proteomics to identify key differences in expression 
of proteins across five representative BCG strains of the four tandem duplication (DU) groups. We 
provide a comprehensive map of single nucleotide polymorphisms (SNPs), copy number variation 
and insertions and deletions (indels) across fourteen BCG strains. Genome-wide SNP characterization 
allowed the construction of a new and robust phylogenic genealogy of BCG strains. Transcriptional 
and proteomic profiling revealed a metabolic remodeling in BCG strains that may be reflected by 
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altered immunogenicity and possibly vaccine efficacy. Together, these integrated-omic data represent 
the most comprehensive catalogue of genetic variation across a global collection of BCG strains.
Tuberculosis disease continues to be one of the world’s leading causes of morbidity and mortality by 
a single infectious agent. The global spread of drug-resistant forms of tuberculosis and the effect of 
HIV-Mycobacterium tuberculosis co-infection in many parts of the world have revived the efforts to 
develop a new vaccine. The currently licensed tuberculosis vaccine, attenuated Mycobacterium bovis 
strain Bacillus Calmette-Guérin (BCG), was originally derived from M. bovis, a virulent member of the 
M. tuberculosis complex that mainly affects wild and domesticated mammals1,2, by repeated passages on 
potato slices soaked in glycerol-ox bile. Since its introduction in 1921, BCG has been used for nearly a 
century to immunize over 3 billion people in at least 180 countries3. It was noted as far back as 1967 that 
its protective efficacy against tuberculosis disease varies substantially between studies, showing an aver-
age risk reduction of pulmonary tuberculosis of 50% and of disseminated and meningitic forms of this 
disease by 70 to 80%4–6. There are several possible explanations for this variable efficacy, including prior 
exposure to non-tuberculous mycobacteria that could block or mask BCG vaccination-induced immune 
responses, the nutritional or genetic background of the human population, and variations between the 
M. tuberculosis lineages present in the world6–9.
Another reason for variation in BCG effectiveness could be differences within and between vaccine 
strains, with potentially considerable heterogeneity among these strains10. Today, fourteen BCG strains 
are currently used worldwide as vaccines against tuberculosis. Early clinical trials in indigenous groups 
in North America, infants in Chicago and school children in the UK demonstrated the efficacy of the 
vaccine and led to its distribution to several countries for worldwide application11,12. The strains used 
are all progenies of the original strain attenuated by Calmette and Guérin during 1909–1921. In the 
absence of lyophilisation or freezing and the production of seed-lots until the 1960 s, the propagation 
of BCG through continuous passage under different laboratory conditions resulted in the generation of 
daughter BCG strains with different morphological, biochemical and immunological characteristics13,14. 
Some of these daughter strains have lost genomic regions that affect their antigenic content, potentially 
changing their protective efficacy15,16. Several studies on BCG strains have demonstrated changes at the 
genome level and comparative genomic studies have uncovered regions of difference (RD) including 
single nucleotide polymorphisms (SNPs), insertion sequences (IS6110), deletions and tandem dupli-
cations16–20. Accordingly, BCG strains are sub-classified into early strains represented by BCG Russia, 
Japan, Moreau, Birkhaug and Sweden that show fewer chromosomal deletions than late strains, such as 
BCG Prague, Glaxo, Danish, Tice, Frappier, Connaught, Phipps and Pasteur21.
The most attributed reason for the primary attenuation of BCG compared to M. bovis is the loss of the 
RD1 locus, which is deleted in all BCG daughter strains and affects the protein secretion pathway ESX-1 
system13,19,22. Although, it has been shown that deletion of RD1 in M. tuberculosis leads to attenuation 
of this strain23, complementation of BCG with this region does not fully restore virulence to wild-type 
levels24, suggesting that other attenuating mutations may have occurred25. A previous study suggested 
that the RDs described to date, including RD2, which is absent from late strains and retained in the 
early strains, might not correlate with the protective efficacy of BCG strains in mice26. In a randomized 
controlled trial in humans BCG Danish (a late strain) and BCG Japan (an early strain) produced higher 
proportions of polyfunctional CD4+T cells than BCG Russia (also an early strain) and BCG Japan also 
led to higher concentrations of secreted Th1 cytokines than either of the other two vaccines27.
While BCG was developed as a vaccine against M. tuberculosis infection, since 1976 it has also been 
used as adjunct therapy for the treatment of bladder cancer and has found favour for the treatment of 
advanced malignant melanoma28,29. For bladder cancer it is highly effective with a recent meta-analysis 
demonstrating a 32% reduction in the risk of recurrence with BCG immunotherapy compared to mito-
mycin C chemotherapy30. Minor adverse events are relatively common and usually as a result of localized 
inflammatory effects31. However, potentially fatal sepsis resulting from dissemination of the live bacteria 
occurs rarely32. A number of the BCG strains are licensed for use in bladder cancer, which, however, 
shows variability in efficacy33.
With differing BCG vaccines strains being used for immunisation and the treatment of bladder can-
cer, it is important to better understand the genetic basis underpinning this evolution and elucidate the 
reasons for variations in levels of protection induced by different BCG daughter strains. We, therefore, 
undertook a systematic and comparative survey of the BCG strains with respect to their genomes, tran-
scriptomes and expressed proteins.
Results
Whole-genome sequencing and phylogeny of BCG strains. We sequenced fourteen BCG 
genomes and one M. bovis isolate to a mean depth of coverage of 250-fold (range 152 to 413) to produce a 
catalogue of differences between the strains. High quality SNPs (as compared to the M. bovis AF2122/97 
reference34) were identified (Fig. 1A) with numbers ranging from nine SNPs and 12 small indels (up to 
10 bp) in the re-sequenced M. bovis to 789 SNPs and 94 small indels in BCG Moreau (Table S1, S2). All 
strains, except BCG Phipps, contained variants that are unique to that individual strain (Table S1).
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A maximum-likelihood phylogeny using SNPs has a similar structure to that seen in previous stud-
ies that were based on tandem duplications and deletions (Fig.  1B). In particular the members of the 
DU2 groups, originally described by Brosch et al.,18, continue to cluster together (Fig.  1B). However, 
the phylogenetic position of BCG Sweden and BCG Birkhaug differs slightly relative to the DU2-based 
Figure 1. (A) A circular representation of Bacillus Calmette-Guérin (BCG) vaccine sub-strains 
chromosomes. Distribution of single nucleotide polymorphisms (SNPs) in fourteen BCG strains compared 
to Mycobacterium bovis AF2122/97. Each coloured blob corresponds to the SNP density in a non-
overlapping window of 10000 nucleotides, with a unique colour per sample allowing easy visual assessment 
of similarities between samples. The scale is shown in megabases in the circle. (B) Phylogenetic relationships 
among BCG strains. Maximum likelihood phylogeny tree based on 700 + variable common nucleotide 
positions across fourteen BCG genome sequences. The tree was rooted using M. bovis AF2122/97.
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classification, where these strains share a common deletion named Δ int, internal of the duplicated region 
DU2 with strains from DU groups III and IV18.
By applying a large indel detection (> 20 base pair) pipeline that has been described earlier35, we 
identified a number of previously unknown deletions and insertions in our analysis (Fig.  2, Table S3). 
An interesting finding is a 103 bp deletion was present across all BCG strains, and eliminates the distal 
end of hspR. This gene is involved in transcriptional regulation (repression) of heat shock proteins and 
known to impact virulence. The hspR locus activates a subset of the heat-shock general stress response 
upon macrophage invasion36, and is necessary in the persistent phase since hspR deletion (Δ hspR) strains 
exhibit attenuated growth in chronic infection37. An analysis of depth of coverage revealed a duplication 
of 2,900 bp segment that spans the region between 1,276,501–1,279,400 base pairs (M. bovis coordinates). 
This duplicated fragment is present in all BCG strains (Fig. S2A).
The key studies on BCG plasticity relied upon DNA arrays, RD screening and Southern blotting of 
restriction digests together with hybridization to estimate genealogies16,18. More recently Garcia Pelayo 
et al., used a minimal set of SNPs to follow the geneology of BCG strains20, followed by Zhang et al. and 
Copin et al., who produced a similar genealogy for BCG vaccine strains, using whole-genome sequencing 
data and de novo assembly38,39. In order to fully interrogate our transcriptome data we produced de novo 
genome assemblies for all fourteen sequenced BCG vaccine strains together with M. bovis. The overall 
genealogy structure is similar to the earlier study38, but with some notable differences (Fig. 2, Table S4).
BCG Connaught was added to the genealogy as part of DU2 Group IV and is very similar to BCG 
Frappier. A 1 bp deletion in phoR and the characteristic deletion of the region Mb3525c to Mb3527c (RD 
Frappier) can be used to identify BCG Frappier. In contrast to other BCG strains and M. bovis, BCG 
Frappier did not seem to show the same partial duplication of gene leuA compared to M. tuberculosis 
H37Rv or M. canettii CIPT 14001005940. The latter gene appears to be a common site for sequence 
duplications amongst M. bovis and BCG strains, for example, with a 202 bp longer leuA gene in M. bovis 
AF2122/97. The lengths and positions of these duplications vary among BCG strains with only BCG 
Frappier containing a leuA with the same structure as that present in H37Rv and M. canettii (Table S5). 
Elevated coverage depth signaled two duplications in the genome of BCG Frappier. These duplications 
comprise 600 bp that encompasses genes Mb0816c-Mb0817 (Fig. S2B) and 1,650 bp that encodes the 
cytochrome oxidase assembly factor ctaB (Fig. S2C).
BCG Tice belongs to the same group as BCG Mexico but can be differentiated by the three genomic 
regions described previously41. Interestingly, in our study BCG China fits into this group. The only previ-
ously sequenced version of this strain contained RD2 as the only major region of difference38. However, 
considerable variation appears to exist between the previously submitted genome of BCG China and 
the strain that was used in our study. Our re-sequencing of BCG China strain demonstrates that it also 
contains the nRD18 deletion, thereby homologous with BCGs Tice and Mexico. To confirm our finding 
Figure 2. Revised genealogy of Bacillus Calmete-Guérin (BCG) vaccine strains. The genealogy of BCG 
vaccine strains, displays the original virulent ancestor strain M. bovis and the subsequent series of genomic 
alteration including deletions of regions of difference (RD), and some strain-specific insertion (‘Ins’) 
and deletions (‘Δ ’). Genes with both insertions and deletions is also shown (‘Indels’). Genetic markers 
identified in this work have been added to the scheme (squares bordered with a red solid line). Note that 
the RD nomenclature in previous work differs between references16,18 deletion of RD816 from BCG strains 
Connaught and Frappier corresponds to RD15 in reference18. Variants shown in boxes are novel in this 
study. All variants shown were manually inspected by read mapping as well as by assembled genomes.
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we mapped the draft genome assembly produced by Zhang et al.,38 to our assembly, which demonstrated 
that the nRD18 region of difference is also present in their original data (Fig. S1). Thus it would appear 
that there are more than one strains named as BCG China in circulation, which clearly belong to differ-
ent branches of the BCG genealogy. While the BCG China strain characterized by Garcia Pelayo et al.,20 
based exclusively on SNPs, clusters with the BCG Danish group of strains (DU2 group III), the BCG 
China strain used in our study is close to the BCG Pasteur strain (DU2 group IV).
As in previous studies BCGs Pasteur and Phipps share considerable homology, with RD14 thought 
to be the primary distinguisher18,38. However, we have shown that both BCG Pasteur and some strains 
of BCG Phipps share this region of difference (Fig. 2, Table S4). It is possible that the original (mother) 
culture of BCG in 1937–1938 actually had a mixed population for RD14, with some bacteria containing 
this region and others having it deleted. The BCG Phipps derived from this mother culture in this study 
appears to have RD14 deleted. Therefore the only key difference that we can be certain of between these 
two strains, which diverged relatively late in the history of the BCG vaccine, is BCG Pasteur’s DU1 
duplication.
The other BCG strains that also constitute the “late” group fall within DU2 Group III. BCG Mérieux 
was unavailable for sequencing but we could confirm that BCG Prague, Glaxo and Danish all belong 
to this group (Fig.  2). BCG Prague continues to be the outlier as it does not contain any deletions in 
phoR but does have a 1 bp insertion in phoP, ensuring this gene’s pseudogenisation due to a frameshift 
mutation (Fig. 2). BCG Glaxo and Danish both share a region of difference in Mb1840–Mb1841, with 
the deletion of a Mg2+ transport ATPase and NADH dehydrogenerase, with relatively minor changes 
differentiating between them: an insertion of 5 bp after Mb2088c (cobalamin biosynthesis protein) in 
BCG Glaxo and a deletion of Mb0097c and Mb0098c in BCG Danish (a common site with variable length 
deletions found in this region in BCG Danish, Sweden, Birkhaug and Moreau).
Finally, BCGs Russia, Moreau, Japan, Sweden and Birkhaug make up the “early” group of strains, 
identified by their intact RD2 region. BCGs Sweden and Birkhaug contain DU2 Group II with a signif-
icant number of shared gene deletions including phoR, Mb0097c and Mb0098c, pks12, trcR and whiB3 
(Fig. 2). The DU2 Group I strains contain an IS6110 upstream of phoP that M. bovis and all other BCG 
strains have lost. Furthermore, our analysis confirmed the DU2-I duplication in BCGs Japan, Moreau 
and Russia demonstrated earlier18. A depth of coverage analysis suggests that DU2-I comprises around 
20 kb of duplication in the region of 3,638,751–3,659,450 base pairs (M. bovis AF2122/97 coordinates). 
Elevated coverage depth was also observed for the direct repeat (DR) region (CRISPR-Cas locus) of these 
strains corresponding to region 3,076,201–3,080,250 base pairs in M. bovis AF2122/97, which encodes an 
IS6110 insertion sequence (Mb2838c-Mb2839c) and many small direct repeats (Fig. S2D).
Drug resistance phenotype to anti-tuberculosis drugs. It has been observed for some time that 
differences exist in the susceptibility of different BCG strains to anti-tuberculosis drugs. As they are 
derived from M. bovis they are all pyrazinamide-resistant due to the H57D mutation in pncA42. In addi-
tion, they are also resistant to cycloserine, partly due to the G122S mutation in cycA43. A previous study 
found that the “early” strains typically have an MIC for isoniazid (INH) of 0.05 μ g/mL, compared to 
BCG strains
Minimum inhibitory concentration (MIC, μg/ml)
Streptomycin Rifampicin Rifabutin Ethambutol Isoniazid
Pasteur 0.125 0.0005 0.002 0.5 1
Japan 0.125 0.0005 0.002 0.5 0.25
Tice 0.125 0.00025 0.002 0.5 1
Danish 0.015 0.000125 0.002 0.5 0,25
Phipps 0.125 0,001 0.002 1 1
Connaught 0.125 0.000125 0.002 1 1
Prague 0.03 0.000125 0.002 1 1.5
Birkhaug — — — — —
Frappier 0.125 0.0005 0.002 1 1
Glaxo 0.125 0.00025 0.002 1 1
Russia — — — 0.5 0.03
Sweden 0.03 — 0.002 0.5 0.015
Moreau — — — — —
China 0.125 00005 0,002 1 1
Table 1.  Drug sensitivity testing of M. bovis BCG strains. The sensitivities of fourteen different BCG 
strains to streptomycin, rifampicin, rifabutin, ethambutol and isoniazid were determined.
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0.1–0.2 μ g/mL for the “late” strains44. This modestly elevated MIC has existed in all strains obtained from 
the Pasteur Institute since 1926.
We repeated this drug susceptibility testing on the BCG strains and found a similar pattern (Table 1). 
Many of the post-1926 strains (BCGs Prague, Glaxo, Tice, Connaught, Phipps and Pasteur) examined 
had raised MIC values, often 1 μ g/mL or greater. BCG China could also be added to this group with 
an INH MIC of 1 μ g/mL. Previously Behr et al.,45 have observed that strains obtained from the Pasteur 
Institute prior to 1927 produced methoxymycolates in vitro but those obtained later could not synthesize 
methoxymycolates. This phenotype has been attributed to a point mutation at position 293 in mma345. 
We found the same SNP in all of the strains with a raised INH MIC, including BCG China (Fig. 2), and 
therefore we postulate that this SNP can lead to low-level INH resistance This is not surprising, as INH 
is known to inhibit the synthesis of α -mycolate, methoxymycolate and ß-mycolate46. The appearance of 
this mutation in BCG China as well as its correlation with phenotypic resistance lends further support 
to it being the mutation responsible for INH resistance.
Transcriptome variation. Genomic differences constitute one possible reason for the observed dif-
ferential phenotypic properties of BCG strains, However, this gives only a partial picture as regulatory 
events occurring on the transcriptional and translational level are largely ignored. A prolonged period 
of culturing under nutrient-rich conditions is bound to have strong selective effects on gene regulation. 
In order to reveal the differences in expression profiles of BCG strains, we performed a global transcrip-
tome analysis across all fourteen BCG vaccine strains grown in vitro focusing on the changes in the 
gene expression profile during exponential growth of the bacilli. RNA extracted from three independent 
exponential phase cultures of M. bovis and daughter BCG strains were used to generate cDNA prepa-
rations that were then analyzed by Illumina-based RNA-sequencing. Data quality was assessed using 
Pearson correlation coefficients (Table S6) and principal component analysis (PCA) (Fig. S3), which 
demonstrated the degree of reproducibility between biological replicates. The total transcriptome data 
are recorded as an average of the clustered samples. A global view of relative expressed profiles of dif-
ferentially expressed genes showed extensive variation in gene expression, both between early and late 
BCG daughter strains and with respect to virulent tubercle bacilli (Fig. S4). This supports the earlier 
genomic observation that the earlier strains are most closely related and cluster together. Quantitative 
RT-PCR analysis of 15 randomly selected target genes was conducted to confirm the validity of the data 
generated through global transcriptional profiles. The qRT-PCR results displayed similar trends of up- 
or down-regulation to those observed in RNA-seq results, supporting the validity and robustness of the 
RNA-seq data (Fig. S5).
To understand potential functional changes arising from differentially expressed genes, enrichment 
analysis of gene ontology (GO) terms across three GO categories—biological processes (BP), molecular 
functions (MF) and cellular components (CC) were investigated (Fig. S6). The overrepresented categories 
in the subset of up-regulated genes include: 1) translation (BP); 2) structural constituent of ribosome 
(MF) and 3) ribosome (CC). While in the down-regulated subset these categories comprised: 1) regu-
lation of transcription, DNA-dependent (BP); 2) sequence-specific DNA binding transcription factor 
activity (MF) and 3) integral to membrane (CC). We observed arginine biosynthetic process pathway 
associated genes were expressed nearly exclusively in BCG Glaxo (Fig. S6).
Metabolic remodelling and adaptations. During in vitro growth, M. bovis is unable to use glycerol 
as a sole carbon source and subsequently unable to use carbohydrates to generate energy due to the lack 
of a functioning pyruvate kinase47, which blocks the ATP-generating roles of glycolysis and the pentose 
phosphate pathway. In line with previous results18, our data showed higher levels of transcription of 
glpD2 across all BCG strains compared with M. bovis linked to the DU2 duplication (Fig. 3A) and strong 
up-regulation of energy production related genes including NDH-1 and the ATP synthase operons (Fig. 
S7). These results reflect the ability of BCG strains to use glycerol as a carbon source and carbohydrates 
to generate energy. By contrast, frdA, aldA, aldB, and nuoJ, encoding fumarate, aldehyde and l-alanine 
dehydrogenase and NADH dehydrogenease I respectively, were suppressed differentially among BCG 
strains (Fig. S7). Additional confirmation of metabolic remodelling is seen in the divergent regulation 
of genes associated with fatty acid degradation (Fig. 3A). Hence, genes that collectively are predicted to 
encode enzymes necessary for the biochemical activation and β -oxidation of fatty acids, including fatty 
acid-coenzyme A (CoA) synthase, acyl-CoA dehydrogenase, enoyl-CoA hydratase and acetyl-CoA trans-
ferase were all divergently regulated among BCG strains. Similarly, a lipid desaturase gene desA3 that is 
putatively involved in fatty acid modification48, was suppressed across all BCG strains compared with M. 
bovis (Fig. 3A). A previous study showed that inactivation of the desA3 gene attenuates M. tuberculosis 
in mice49, suggesting a key role for this lipid desaturase gene in virulence. Taken together, these data 
support the view that BCG uses glycerol as a carbon source during in vitro growth47, and provides clues 
to an alternative mechanism by which BCG is attenuated.
Lastly, remodelling of the cell surface and lipid metabolism is indicated by the divergent regulation 
of the genes involved in phthiocerol dimycocerosate (PDIM) and mycolic acid synthesis (Fig.  3B,C). 
Whereas mycolic acid synthesis appeared suppressed in BCG compared to M. bovis, we noted marked 
induction of the synthesis of mycolic acids consistent with the induction of umaA2, accD4, accD5, 
mmaA2, inhA, fbpA, fbpB, fabG1 and Mb3433 (Fig. 3B). Altogether, our results indicate that BCG strains 
www.nature.com/scientificreports/
7Scientific RepoRts | 5:15443 | DOi: 10.1038/srep15443
vary in their cell wall composition compared to M. bovis, providing another explanation for both altered 
immunogenicity and variable drug resistance.
Adaptations in regulatory and virulence genes. In line with the metabolic remodelling, the expres-
sion of several transcriptional regulators was divergent between M. bovis and BCG strains (Fig.  3D). 
Several transcription factors are up-regulated in BCG such as hspR, Mb0361, Mb0841, Mb1433c, and 
Mb3702c. Similarly, the RNA polymerase sigma factor sigA was up-regulated in all strains except BCG 
Russia (Fig. 3D). This sigma factor has previously been recognised as differentially expressed in virulent 
versus avirulent strains of M. tuberculosis50. Other up-regulated RNA polymerase sigma factors are sigB, 
sigE, sigH, sigM. Differential expression is seen among the whiB family of transcription factors, which 
regulate virulence, stress responses and cell division51–53. whiB1, whiB2 and whiB3 were overexpressed, 
while whiB4 was down-regulated in BCG strains compared to M. bovis. Interestingly, data revealed that 
differential expression of transcriptional activators showed the least variation in BCG Russia (Fig. 3D).
Analyses of genes encoding virulence and immunogenic surface and secreted proteins also revealed 
variable levels of gene expression profiles across BCG strains. Several virulence factors required for cell 
invasion or escape such as mkl (mceG), thought to be essential for the function of the mce loci involved in 
nutrient uptake, are suppressed in all BCG strains except BCG Tice (Fig. 3E). Strikingly, our results show 
that mce2A, mce2B, mce2C, mce2D, mce4A, yrbE4A and yrbE4B are highly suppressed in BCG Pasteur, 
Moreau, Connaught and Frappier whereas mce1R showed increased expression across all BCG except 
Russia (Fig. 3E). mce1R is a transcriptional regulator of mce1 operon54 and this overexpression suggests 
increased negative regulation of mce1 operon and therefore may be relevant to attenuation.
In line with an earlier report55, expression of the antigenic region that encodes the major secreted 
immunogenic proteins Mpb70 and Mpb83 were significantly suppressed in late BCG strains as well as 
the immunogenic protein Mpb64, which have been deleted from the later strains (RD2) and suppressed 
in the earlier strains (Fig. 3F). Furthermore, several immunogenic factors such as ESAT-6 like proteins 
(esxC, esxD, esxG, esxH, esxK, esxI, esxJ, esxL, and esxM) as well as lprG are up-regulated in all BCG 
strains, suggesting that this could be a compensation for ESAT-6 deletion. Interestingly, three ESAT-6-like 
genes (esxQ, esxR, and esxS) showed reduced expression compared with M. bovis (Fig. 3F). Importantly, 
it is worth noting the variable expression of PE and PPE families, including PE_PGRS proteins, (Fig. 
S8) thought to be responsible for the antigenic diversity56. Interestingly, we observed over expression 
of ESX-5 locus genes including esxN, pe18, ppe25, ppe26 and ppe27 exclusively in BCG Tice as a result 
of ESX-5 locus duplication in BCG Tice57 (Fig.  3, Fig. S8). Duplication of the ESX-5 locus could be 
selected for by certain growth conditions, as recent research has indicated the ESX-5 is involved in outer 
Figure 3. Transcriptional profile of a global collection of BCG strains: Gene expression heat maps 
of genes showing expression profiles involved in; (A) Catabolism of fatty acids. (B) phenolpthiocerol 
dimycocerosate (PDIM). (C) mycolic acid synthesis. (D) Transcriptional regulatory. (E) Mammalian cell 
entry genes. (F) Immunogenic surface and secreted proteins. Genes were selected based on their annotation. 
The color scales represent log2-fold changes in gene expression (DESeq), using the M. bovis AF2122/97 
strain as reference.
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membrane permeability and nutrient import58. Finally, T cells are potent effectors of acquired immunity 
against intracellular bacterial pathogens including Mycobacterium species. It has been observed pre-
viously that most BCG T-cell epitopes are highly conserved at sequence level38, however, our analysis 
demonstrated a highly diverse T cell antigen expression profile when compared to M. bovis (Fig. S9).
Pairwise comparison of high and low immunogenicity strains. The most thorough randomised 
clinical trial of different BCG vaccines to date compared the immune responses of newborn infants to 
BCG Danish, Japan and Russia27. The proportion of polyfunctional CD4+ T cells was significantly higher 
in the infants immunised with BCG Danish or Japan compared to Russia. Infants immunised with BCG 
Japan also had higher concentrations of secreted Th1 cytokines and infants immunised with BCG Danish 
had higher proportions of CD107 expressing cytotoxic CD4+ T cells. This suggests that BCG Japan and 
BCG Danish could be more immunogenic than BCG Russia. This finding led us to particularly explore 
the transcriptional differences among these strains.
Both BCG Japan and BCG Danish had a number of genes that showed significantly greater expression 
than the equivalent genes in BCG Russia. For BCG Japan 348 genes were up-regulated and 541 genes 
were down-regulated compared to BCG Russia. Our analysis showed an enrichment of genes involved 
in transport, DNA-mediated transposition, DNA metabolism and oxidation-reduction processes in the 
list of down-regulated genes (Fig.  4A). Of these, oxidation-reduction was the largest group containing 
67 genes, followed by DNA metabolic processes containing 32 genes. For genes up-regulated in BCG 
Japan compared to Russia, these predominantly consisted of genes involved in translation including 11 
ribosomal proteins from the 30 S subunit and 13 proteins from the 50 S subunit (Fig. 4A).
In the comparison between BCG Danish and BCG Russia, 107 genes were up-regulated and 39 were 
down-regulated. No clear enrichment was evident for the genes down-regulated in BCG Danish with 
sharing a nucleoside metabolic process (Fig. 4B). However for the up-regulated genes an enrichment of 
genes involved in translation was again seen with two being 30 S subunit ribosomal proteins and five 
being 50 S proteins (Fig. 4B).
Comparison of BCG proteomes. BCG strains are classified into four groups (I-IV) based on RD and 
DU2 markers18. However, our phylogeny produced on genome-wide SNP-differences (SNP-barcodes) 
Figure 4. Pattern of increased and decreased expression in genes of BCG Japan and Danish compared 
to our own assembled genome of BCG Russia. (A) Genes that are significantly down-regulated or up-
regulated in BCG Japan compared to BCG Russia. Genes are categorized based on significant enrichment in 
biological processes of gene ontologies (p < 0.05). Left: total number of genes found to be down-regulated 
in each biological process category. Right: total number of genes found to be up-regulated in each biological 
process category. (B) Genes that are significantly down-regulated or up-regulated in BCG Danish compared 
to BCG Russia. Genes are categorized based on significant enrichment in biological processes of gene 
ontologies. Left: total number of genes found to be down-regulated in each biological process category. 
Right: total number of genes found to be up-regulated in each biological process category.
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re-classified BCG isolates into five groups (Fig. 1B). Coupled with our understanding of the global tran-
scriptional profile, we performed quantitative protein analysis on five representatives of these groups. 
Using a mass spectrometric approach with tandem mass tagging for quantification (TMT)-labeling, we 
identified a total of 794 proteins and determined their differential expression (detailed in Table S7). 
For a global overview of key changes in metabolism, proteins displaying high differential regulation 
(2-fold change differences) were grouped into functional categories based on the Bovilist/TubercuList 
server classification59. The highest level of diversity in expressed proteins related to information path-
ways and intermediate metabolism and respiration (Fig. S10), again reflecting the metabolic remodeling 
as discussed earlier. Differential regulation was also observed for proteins involved in cell wall and cell 
processes and lipid metabolism (Fig. S10).
On the basis of these findings, we subsequently focused on metabolic pathways connected to synthesis 
or energy production. Proteins mapped to these metabolic pathways were selected and their differential 
regulation was presented in a heat map (Fig. 5). We regarded proteins showing an increase or decrease 
with a fold change ≥ 2.0 as strongly expressed, those with fold change ≥ 1.5 but < 2.0 as moderately 
regulated and proteins with fold change < 1.5 as not regulated. Components of the ATP synthase com-
plex, NADH dehydrogenase and ubiquinol-cytochrome C complex were divergently induced (Fig. 5A). 
Moreover, enzymes of the glycolytic pathway, components of the tricarboxylic acid cycle and the pyruvate 
dehydrogenase complex, an enzyme linking glycolysis with the tricarboxylic acid cycle, were displaying 
differential regulation (Fig. 5A). Among the expressed proteins, some have been previously described as 
virulence proteins in different strains of M. tuberculosis complex including heat shock protein HspX, the 
secreted antigen 85-A and C, GroELs, phosphoenolpyruvate carboxykinase (pckA), isocitrate lyase (icl), 
3-oxoacyl synthase II (kasA) and alkyl-hydroperoxide reductase (ahpC)60–62 (Fig. 5). Induction was also 
observed for various components of the stress response, including heat shock proteins, co-chaperonins 
proteins and bacterioferritins (Fig. 5A). Induction of these facilitators of protein re-folding may contrib-
ute towards optimizing the integrity of synthesized proteins or to recycling of existing proteins.
Figure 5. Heat map of differentially expressed proteins among five representative BCG strains 
compared to M. bovis. Differential expression of proteins involved in biochemical pathways related to 
energy metabolism (A), or to biosynthesis pathways (B,C) are shown. The color scale indicates differential 
regulation as the Fold Change of the protein amount relative to the M. bovis 2122/97 reference strain. Up-
regulation is indicated in red, down-regulation in blue. Star (*) indicates lack of correlation with RNA-seq 
data for that gene.
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Furthermore, major biosynthetic pathways were generally found divergently regulated among BCG 
strains, including ribosomal protein synthesis, DNA biosynthesis and synthesis of mycolic acids, a key com-
ponent of the mycobacterial cell envelope63 (Fig. 5B,C). Variation in expression was observed for several 
polyketide synthases, several ribosomal subunits and for DNA helicase and a ribonucleotide-diphosphate 
reductase subunit, which are components of lipid, protein and DNA biosynthesis, respectively (Fig. 5C). 
Taken together, the observed changes in the BCG strains proteome support the results obtained from the 
transcriptome study and reflect how in vitro growth adaptation causes phenotypic differences amongst 
the BCGs.
Discussion
Although BCG is the only licensed vaccine against tuberculosis, its history has been clouded by vari-
able efficacy and reports of strain variability in morphology, growth rate, gene/protein expression and 
genetic make-up64. Several reasons have been suggested to explain the varying protective efficacies of 
BCG, including the genetic differences between vaccines strains as well within a given sub-strain17,18. In 
this study, we have surveyed the heterogeneity among BCG strains through a combination of genome 
sequencing, comparative transcriptome and proteome analyses. Our combined approach has enabled us 
to identify signatures of genetic and transcriptomic variability across fourteen BCG strains, which may 
play critical role in observable differences in vaccine efficacy between them.
One signature, consistent with the previous study18, is that the SNP phylogeny is congruent with the 
genealogy constructed based on large insertions and deletions. For BCG China, our result and the previ-
ous finding were discrepant. An earlier report claimed that BCG China is a successor of BCG Danish and 
displays the DU2-III duplication57. However, our analysis places BCG China into the group of DU-IV 
strains, which asks for a closer inspection of the source of the previously sequenced BCG China strain 
in comparison with the BCG China strain used in our study. It also raises a concern that multiple cir-
culating strains of “BCG China” may be present and these may lead to the production of vaccines with 
varying immunogenicity with the same name-tag.
Genomic profiles of BCG Sweden and BCG Birkhaug are similar and they shared similar deletions57. 
Our study revealed a novel deletion locus shared by these two strains together with Russia and Frappier, 
which distinguishes them from other BCG family members (Fig. 2). The variably sized deletions concerned 
the pks12 gene, which encodes polyketide synthase 12, known to be necessary for β -phosphomycoketide 
(MPM) production and the CD1c-mediated T-cell response65. Deletion of pks12 genes in each of M. 
tuberculosis strains H37Rv, CDC1551, and BCG Pasteur strains completely abolished the ability of all 
three strains to activate CD1c-restricted T-cells and to produce mannosyl-β -1-phosphoisoprenoids 
(MPI)65. It is therefore possible that deletions within pks12 may directly affect the immunogenicity of the 
vaccine as CD8-1-reactive MPM cannot be detected in non-pathogenic mycobacteria such as M. smeg-
matis, M. phlei and M. fallax65. The pks12 gene has not been found in any non-pathogenic mycobacteria, 
suggesting a possible direct effect on virulence. Deletions of pks12 have also been shown to increase drug 
resistance in Mycobacterium avium through a cell wall–remodeling pathway, although the impact of this 
on BCG strains is currently unknown66.
Apart from the use of BCG strains in vaccinology, BCG strains have also been used in immuno-
therapeutic applications in bladder cancer treatment. However, higher bacillic doses are required for 
bladder cancer immunotherapy (108–109 bacilli) than for either oral BCG vaccination (107 bacilli) or 
intradermal vaccination (105 bacilli). This may explain the higher likelihood of disseminated infection 
in immune-compromised individuals undergoing this treatment. Furthermore, variations in efficiency of 
immunotherapy has been observed between BCG Connaught and BCG Tice in bladder cancer patients33, 
which might be linked to a point mutation in the sodC dismutase encoding gene of BCG Tice that we 
also have confirmed.
Moreover, BCG strains may also differ in their antibiotic resistance levels. A previous study demon-
strated that all BCG strains obtained from Pasteur Institute after 1926 had moderately elevated levels 
of resistance to INH44 and this phenotype coincides with a point mutation in the mma3 gene, resulting 
in impaired methoxy mycolic acid production45. Our analysis of mma3 genes in BCG strains confirms 
the same mutation in all late BCG strains, including BCG China, and we believe that this mutation is 
causative for the moderately elevated levels of resistance to INH. Our result establishes that there are 
significant differences in the sensitivity to INH between the earlier and later BCG isolates, a finding that 
has important implications for BCG immunotherapy.
Analysis of the transcriptome of the strains shows remarkable variation in gene expression, both 
between early and late strains and within groups of BCG strains. In particular, changes in the expression 
of certain cell envelope components suggest that BCG daughter strains have adapted to their environ-
ments by the divergent regulation of fatty acid-degrading enzymes and DNA repair proteins, and the 
remodelling of their envelopes. Many of the cell wall components of M. tuberculosis have been associated 
with virulence and modulation of the host immune response67. Although the function of lipoproteins in 
mycobacteria have not been well characterized, some lipoproteins such as phospholipase C have been 
reported to modulate the host immune response and may play an important role in virulence68. Similar 
functions have also been attributed to some exported proteins69. We hypothesize that this regulation of 
a series of genes involved in the synthesis of cell wall and cell membrane components may impact upon 
BCG attenuation and the vaccine’s variable efficacy.
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The up-regulation of genes involved in translation in both BCG Danish and BCG Japan when com-
pared to BCG Russia suggests an increase in expression of ribosomal proteins. It is not surprising that the 
induction and expression of ribosomal proteins increases the immunogenicity of a vaccine, first observed 
when guinea pigs immunized with a ribosome-rich fraction of the avirulent Mycobacterium tuberculosis 
H37Ra were protected against subsequent infection by the virulent H37Rv70. Subsequent work has shown 
that the 50 S subunit provokes a strong delayed-type hypersensitivity reaction in sensitized guinea pigs71 
and that whole ribosomes are required for this reaction, not just the protein or RNA components72. 
Similarly studies on blood samples from BCG-vaccinated healthy volunteers showed increased cell pro-
liferation and interferon-gamma responses related to the immune-dominance of detergent phase frac-
tions of M. tuberculosis that were ribosomal protein-rich73, many of which are membrane-associated74. 
This increase in ribosome production in carbon-limited BCG cells is subject to growth rate-dependent 
control75. Therefore we suggest that the propensity of BCG Danish and BCG Japan to increase their ribo-
some number through increased gene expression may directly lead to their increased immunogenicity, 
emphasizing the importance of ribosome abundance in effective tuberculosis vaccines.
The proteome analysis with relative quantification labeling of the selected BCG strains reveals a 
profile consistent with their transcription, with proteins functionally involved in biosynthesis, energy 
metabolism and virulence, detoxification or adaptation significantly over-represented in BCG strains 
as compared to M. bovis. Components of stress response heat shock proteins strongly up-regulated in 
BCG Phipps while co-chaperonin GroEL and GroES, were strongly up-regulated in BCG Japan and 
Birkhaug. GroEL1 and 2 are chaperonins participate in folding of newly synthesized, imported, unfolded 
or poorly folded proteins as well as being involved in the heat-shock response. GroEL1 (Mb3451c) is a 
potent inducer of cytokine synthesis, including interleukins (IL) IL-1β , IL-6, IL-8, IL-12, tumor necrosis 
factor-α (TNF-α ) and granulocyte-macrophage colony-stimulating factor (GM-CSF)76, while GroEL2 
(MB0448) is shown to be a key element for mycobacterial-survival inside macrophages and is well rec-
ognized by the immune system, in vitro and in vivo77. Overexpression of these proteins including AhpC 
could be a survival mechanism for these strains, prolonging their intracellular stay in macrophages and 
allowing for more efficacious antigen processing and presentation, concomitantly with increased protec-
tion as result of prolonged immune system activation. On the other hand, since these proteins are a key 
element for virulence, there appears to be a positive correlation between virulence level and protective 
efficacy of vaccine strains. A similar correlation was observed in early animal studies78,79. Furthermore, 
the cumulative effects of variation in secreted and cell wall antigens across BCG strains may contribute to 
variable vaccine efficacy. Taken all together, these findings add to the growing evidence that BCG vaccine 
strains differ too widely to be considered a single vaccine for comparative and regulatory purposes. We 
propose that a single vaccine strain should be chosen and used for global vaccination purposes to prevent 
exposing populations to a less immunogenic or more drug resistant strain of BCG. Future systematic 
studies on comparative efficacies of all of these BCG vaccine strains in various host backgrounds will 
help to determine the most effective vaccine strain that may be recommended under a given set of envi-
ronment including host immune status. Our results provide a comprehensive framework to understand 
the underlying genomic variability and the gene and protein expression readouts for such variability, 
resulting from nearly 100 years of in-vitro evolution since the vaccine was first developed.
Methods
Bacterial strains and growth conditions and DNA isolation. Mycobacterium bovis BCG substrains 
were collected from Marcel Behr, McGill University, BCG China from Baoli Zhu, Chinese Academy of 
Sciences and Mycobacterium bovis from Roland Borsch, Institute Pasteur. Bacteria were grown at 37 °C 
on Middlebrook 7H10 agar plates supplemented with 10% OADC (oleic acid–albumin–dextrose–cata-
lase, BD Biosciences) or in shaking cultures in Middlebrook 7H9 liquid medium supplemented with 10% 
ADC (albumin–dextrose–catalase, BD Biosciences) and 0.05% Tween 80. Genomic DNA was prepared 
using the bead beater–phenol/chloroform extraction method.
Genome Sequencing and Assembly. Paired-end genomic libraries were prepared using TruSeq 
DNA Sample Preparation Kits V2 (Illumina Inc, San Diego, CA, USA) and sequenced on an Illumina 
HiSeq 2000. Raw reads were trimmed with Trimmomatic80 to an average quality score of 20 within a win-
dow size of 4 bp. Initial contig assembly was performed with Velvet81, using VelvetOptimiser to choose 
kmer values ranging from 33 to 81 [http://www.vicbioinformatics.com/software.velvetoptimiser.shtml]. 
Contigs were orientated and ordered with M. bovis AF2122/97 (EMBL accession number BX248333.1) 
as the reference genome and scaffolding and iterative gap filling were performed using PAGIT toolkit82.
Genome alignment and phylogenetics. The raw paired-end reads were also mapped against the 
reference M. bovis genome using BWA83. SNPs were identified using Samtools84 and filtered to ensure 
that they had a quality score more than 30 and were present in at least 75% of the mapped reads in 
each direction. The reference genome was segmented into 5000 bp non-overlapping sliding windows 
per sample. The SNP density in each of these windows was represented by a colored circle in Fig. 1A, 
with different colours representing different samples. This Figure was composed using the Circos visu-
alization package [http://circos.ca]. Filtered SNPs were also concatenated and used as alignments for the 
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estimation of a maximum likelihood phylogeny using the default settings of RAxML v0.7.4. 100 initial 
trees were generated and the best tree identified, followed by the production of 100 bootstraps.
Detection of indels. Large deletions were detected as described35. Briefly, large deletions (> 100 bp) 
were determined using a combination of tools based on paired-end, split-read and depth of coverage 
approaches. Reads at putative deletions (300 bp) predicted by all five tools were extracted from bam files 
and subsequently de novo assembled using Velvet81. If a derived contig happened to be split into two 
parts when mapping it back to the reference with high similarity (> 95%), the contig was considered a 
cross-junction contig (CJC)85. Deletions without at least one CJC were considered to be false positives 
and were therefore discarded. Deletions in PE/PPE genes were filtered out due to the complexity of such 
regions. All validated deletions were gathered and merged when having a mutual overlap greater than 
90%. Insertions were detected by performing de novo assembly and aligning resulting contigs to the ref-
erence genome in order to find novel sequences present in the target genome and absent in the reference.
RNA isolation and purification. Forty milliliters of exponential growth phase culture was harvested 
at an OD600 of 0.6. Bacteria were re-suspended in 1 ml of TRIzol (Invitrogen) and added to a 2-ml 
screw-cap tube containing 0.5 ml zirconia beads (BioSpec Products). Bacterial cells were disrupted by 
bead-beating 5x for 30 seconds with a 1-minute interval on ice. After centrifugation of lysed mycobac-
teria, supernatants were extracted with chloroform and RNA was precipitated with sodium acetate (2 M, 
pH 5.2) and isopropanol. RNA pellets were washed with 75% ethanol and resuspended in RNase-free 
water. Contaminating DNA was removed with RNase-free DNase (Fermentas) prior to RNA purification 
through an RNeasy MinElute Cleanup kit (Qiagen). The quality of RNA was assessed using a Nanodrop 
(ND-1000, Labtech) and the Agilent 2100 Bioanalyzer (Agilent; Palo Alto, CA, USA) as per manufac-
turer’s recommendations.
Enrichment of mRNA from total RNA and Library preparation for RNA-seq analysis. As ribo-
somal RNA comprises the vast majority of the extracted RNA population, depletion of these molecules 
through RiboMinus-based rRNA depletion, has been used in efforts to increase the coverage of mRNA 
and to reduce rRNA reads. For this mRNA enrichment, the Invitrogen’s RiboMinusTM Prokaryotic kit 
was used according to manufacturer’s instructions.
Construction of double-stranded cDNA libraries preparation was carried out essentially using 
Illumina TruSeqTM RNA sample preparation kit V2 according to manufacturer’s protocol.
Illumina sequencing and Transcriptome (RNA-seq) data analysis. The bar-coded cDNA librar-
ies were pooled together in equal concentrations in one pool before sequencing on Illumina HiSeq2000 
using the TruSeq SR Cluster Generation Kit v3 and TruSeq SBS Kit v3. Data were processed with the 
Illumina Pipeline Software v1.82.
Sequence reads of the different conditions were mapped against the reference sequence of M. bovis 
AF2122/97 strain as paired end data using SMALT. The read counts were used in DESeq86 to first gen-
erate a distance matrix and PCA plots (Fig. S3, plotPCA function). Differential expression analysis 
(DESeq86) was performed pairwise between individual BCG strain and M. bovis AF2122/97 strain, using 
the default parameter. For the up down regulated genes of each comparison, a GO enrichment was done, 
using the R package TopGO, default parameter (http://www.bioconductor.org/packages/2.11/bioc/html/
topGO.html). GO terms were obtained from EBI [ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/proteomes/].
Quantitative RT-PCR. The reliability of the RNA-seq expression data was assessed using quantitative 
real-time reverse transcriptase PCR (qRT-PCR) analysis. Briefly, 200 ng of total RNA was used to gen-
erate cDNA using SuperScript III reverse transcriptase (Invitrogen). QPCR was performed using SYBR 
GreenER QPCR kit (Invitrogen) and the 7900HT Fast Real-Time PCR System (Applied Biosystems). Ct 
values of target genes were normalized to values obtained for the mycobacterial housekeeping gene sigA. 
In total, 15 genes involved in different pathways were randomly selected for verification of RNA-seq data 
(Table S8).
Whole cell lysate preparation and tandem mass tagging (TMT) quantification. For proteome 
analysis, M. bovis BCG Pasteur, Phipps, Danish, Japan and Birkhaug exponential growth phase cultures 
were harvested at an OD600 of 0.6 and washed twice and suspended in PBS for lysis. Cellular proteins 
were obtained by bead beating using 425–600 μ m glass beads (Sigma) in the presence of a protease 
inhibitor (PMSF, 20 mM). The extracted proteins were quantified using the BCA protein assay (Thermo 
Scientific, USA). A total of 100 μ g of each protein sample was reduced in tris (2-carboxyethylphosphine), 
alkylated using methyl-methanethiol-sulfonate (MMTS) and digested with trypsin. Tryptic digests were 
dried, resuspended in triethylammonium bicarbonate (pH 8.5) and labeled with 6plex TMT reagents 
(Thermo Scientific) according to the manufacture manual. The labeled peptides were pooled and frac-
tionated using strong cation exchange chromatography. The LC-MS/MS analysis of the peptide frac-
tions using an LTQ-Orbitrap Velos (Thermo Scientific) coupled with an Easy-nLC (Thermo Scientific) 
and the MS data processing were carried out following our published procedure87. Briefly, the MS 
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spectra were extracted using Proteome Discoverer software (http://www.thermoscientific.com/en/prod-
uct/proteome-discoverer-software.html) and processed by an in-house script before Mascot search against 
the database for M. bovis sequence (EMBL accession number BX248333.1). The resulting files were then 
processed by Scaffold (Proteome Software Inc., USA) for validation of MS/MS based peptide and protein 
identifications. Peptide and protein identifications were reported if they could be established at greater 
than 95.0% probability. Scaffold local false positive rates for peptide and protein were controlled within 
1%. The peptide and protein quantitation were performed using Scaffold Q + (Proteome Software Inc).
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